Featured Story | Wednesday, June 10, 2020 AbbVie is set to pay Genmab $750 million upfront for a stake in a pipeline of anti-cancer bispecifics led by epcoritamab. The deal, which features up to $3.2 billion in milestones, positions AbbVie to race Regeneron to market with a bispecific antibody that could compete with CAR-T therapies. read more |
| |
|---|
|
Top Stories Tuesday, June 9, 2020 The COVID-19 pandemic has thrown a curve ball at the global economy, and the biopharma industry is no exception. Companies are scrambling to develop tests, treatments and vaccines for the disease, while making sure not to neglect their pipelines. We caught up with Ioannis Sapountzis, Boehringer Ingelheim’s global head of business development and licensing, to see how the German pharma is handling this. read more Wednesday, June 10, 2020 Eli Lilly is pretty busy with a series of partners working at breakneck speed on its antibody hopefuls for COVID-19, but that hasn’t stopped it from penning a new pipeline pact in central nervous system diseases. read more Wednesday, June 10, 2020 Hoping to carve out a niche in a tough market full of competitors while also keeping down safety issues, Pfizer has posted yet more positive data in atopic dermatitis. read more Wednesday, June 10, 2020 Five years ago, Neil Kumar, Ph.D., quit his job at Third Rock Ventures to start a new kind of biotech company. The idea was "Moneyball" for biotech—to pick up potential rare disease treatments languishing in academia and to develop enough of them in parallel that the rare focus wouldn’t scare off investors. read more Wednesday, June 10, 2020 Illumina received an emergency authorization from the FDA for its COVID-19 test designed to sequence the full genome of the novel coronavirus. read more Wednesday, June 10, 2020 A new study from the University of Zaragoza in Spain has found what could be SARS-CoV-2’s Achilles’ heel—a protein that’s critical for the reproduction of the virus. The researchers argue it could make an excellent target for potential inhibitors of the virus. read more Tuesday, June 9, 2020 Biopharma M&A has seen a sharp decline so far this year, both in terms of monetary value and total transaction count, amid a COVID-19 business slowdown. But executives from Johnson & Johnson, Takeda and Horizon Therapeutics said their companies' M&A strategies remain unchanged. read more |  | Your product is important, and your trial deserves the team that has what it takes. It takes knowledge. It takes passion. It takes commitment. It Takes Avania. Learn more. |
Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Position yourself as a precision medicine leader with the online graduate program in precision medicine. Learn the latest in genomic technologies and precision medicine therapies from experts in research and implementation. Join the future of health care with the flexibility and convenience of an online program. |
| |
|---|
|
Resources Sponsored by: ICON Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency. Sponsored by: Catalent In a series of innovation sessions, Catalent RP Scherer softgel capsules were quickly identified as the ideal solution to drive incremental growth. Learn more. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe. Sponsored by: Clinical Ink This white paper covers a Phase III case study; BYOD advantages and misconceptions; and regulatory, copyright, and equivalency considerations. Sponsored by: Clinical Ink Learn how GI specific data capture solutions can support virtual and hybrid trials during COVID-19. Sponsored by: Copyright Clearance Center Dive into the history of biomedical classification and how these systems have evolved to address new technology and use cases. Presented by: ICON Clinical Research Download this whitepaper to learn more about the success factors that are required to keep a pandemic respiratory vaccine trial running at optimal speed and efficiency. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. Sponsored by: Frontage Laboratories, Inc. Listen to our brand-new Frontage Laboratories podcast where you’ll take home tips for developing residual host cell proteins ELISA assay for biopharmaceutical products using commercial kits. Wednesday, May 20, 2020 | Time: 10am-3.30pm (BST) Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research. Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Outer Edge Technology Businesses must maintain pre-pandemic levels of productivity with smaller IT budgets. Learn why an effective Cloud Strategy is imperative for success in these unprecedented times. | 
